Topics

PubMed Journals Articles About "GOLimumab And Methotrexate Versus Methotrexate In Very Early PsA (GOLMEPsA)" RSS

07:28 EST 29th January 2020 | BioPortfolio

GOLimumab And Methotrexate Versus Methotrexate In Very Early PsA (GOLMEPsA) PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest GOLimumab And Methotrexate Versus Methotrexate In Very Early PsA (GOLMEPsA) articles that have been published worldwide.

More Information about "GOLimumab And Methotrexate Versus Methotrexate In Very Early PsA (GOLMEPsA)" on BioPortfolio

We have published hundreds of GOLimumab And Methotrexate Versus Methotrexate In Very Early PsA (GOLMEPsA) news stories on BioPortfolio along with dozens of GOLimumab And Methotrexate Versus Methotrexate In Very Early PsA (GOLMEPsA) Clinical Trials and PubMed Articles about GOLimumab And Methotrexate Versus Methotrexate In Very Early PsA (GOLMEPsA) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GOLimumab And Methotrexate Versus Methotrexate In Very Early PsA (GOLMEPsA) Companies in our database. You can also find out about relevant GOLimumab And Methotrexate Versus Methotrexate In Very Early PsA (GOLMEPsA) Drugs and Medications on this site too.

Showing "GOLimumab Methotrexate Versus Methotrexate Very Early GOLMEPsA" PubMed Articles 1–25 of 13,000+

Risk of serious infection among initiators of TNF inhibitors plus methotrexate versus triple therapy for rheumatoid arthritis: a cohort study.

To compare the risk of serious infections between the TNF inhibitor (TNFi) plus methotrexate (MTX) versus triple therapy among RA patients in a real-world setting.


Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.

To provide the first direct comparison of patient-reported outcomes (PROs) following treatment with tofacitinib monotherapy versus tofacitinib or adalimumab (ADA) in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) with inadequate response to MTX (MTX-IR).

Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.

Umbilical cord blood transplantation (UCBT) is a curative treatment for hematological malignancies. However, appropriate prophylaxis against graft-versus-host disease (GVHD), aimed at obtaining rapid and stable engraftment and avoiding toxicity, remains controversial in UCBT. We retrospectively compared outcomes in 409 patients who received calcineurin inhibitors (CIs) plus conventional-dose methotrexate (conv-MTX/CIs, n = 77; methotrexate, 10 mg/m on day 1, 7 mg/m on days 3 and 6) with those who received C...


Two cases of severe neutropenia in patients on low-dose methotrexate and ceftriaxone.

There are limited data on the effect of ceftriaxone on methotrexate clearance, with results of some studies indicating altered methotrexate pharmacokinetics with the administration of ceftriaxone. We describe 2 possible cases demonstrating an interaction between methotrexate and ceftriaxone, resulting in profound neutropenia.

Increased methotrexate intolerance in juvenile idiopathic arthritis compared to acute lymphoblastic leukaemia in children.

To analyse the internal consistency of an adaption of the methotrexate intolerance severity score (MISS); and to describe and compare the level of methotrexate intolerance evaluated by the MISS in Danish children with juvenile idiopathic arthritis (JIA) or acute lymphoblastic leukaemia (ALL), treated with low-dose methotrexate (MTX).

Primary Intraocular Methotrexate-related Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis Undergoing Long-term Methotrexate Therapy.

Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate.

To evaluate the long-term efficacy and safety of maintaining baricitinib monotherapy in patients with active rheumatoid arthritis (RA) originally treated with baricitinib monotherapy or switched from methotrexate (MTX) or the combination of baricitinib plus MTX to baricitinib monotherapy.

Successful treatment using Actinomycin D in a case of methotrexate-resistant ectopic pregnancy: A case report.

Ectopic pregnancy is an urgent clinical condition that represents a serious hazard to reproductive power, and thus threatens woman's health. Commonly, methotrexate is considered for early resolution of placental tissue. Despite its potential advantages such as minimizing hospitalization and quick recovery, its high skin and gastrointestinal side-effects and requiring time monitoring may limit its application. Recently, high effectiveness of the single-agent chemotherapy agents, such as Actinomycin D, has be...

Delayed methotrexate clearance and acute kidney injury after high-dose methotrexate chemotherapy concurrent with dasatinib in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report.

Severe toxic effects of low-dose methotrexate treatment for placenta accreta in a patient with methylenetetrahydrofolate reductase mutations.

Low-dose methotrexate (LDMTX) has been widely used for many decades in clinical settings, with good safety profiles compared with those of high-dose methotrexate. LDMTX is also used as one of the off-label conservative therapies in treating placenta accreta (PA). Until now, only a few mild adverse drug reactions (ADRs) have been published after short-term use of LDMTX, and no severe cases have been reported.

Topical methotrexate 1% gel for treatment of vitiligo: A case report and review of the literature.

Vitiligo is quite a common hypopigmentary disorder, which may affect both children and adults with important psychological effects due to the well-known leopard skin-like appearance. Even if asymptomatic and not life threatening, vitiligo has to be increasingly studied and treated. Hitherto, the efficacy of topical methotrexate in treatment of vitiligo has not been reported. We herein reporting our preliminary observation on the promising efficacy of topical methotrexate in 1 patient with stable vitiligo. T...

The Protective Effect of Cilostazol in Genotoxicity Induced by Methotrexate in Human Cultured Lymphocytes.

Methotrexate is an antagonist of folic acid that has been shown to be genotoxic to healthy body cells via induction of oxidative stress. Cilostazol is a phosphodiesterase III inhibitor and a strong antioxidant drug.

Optimising Low Dose Methotrexate for Rheumatoid Arthritis - A Review.

Methotrexate at low doses (5-25 mg/week) is first-line therapy for rheumatoid arthritis. However, there is inter- and intra-patient variability in response, with contribution of variability in concentrations of active polyglutamate metabolites, associated with clinical efficacy and toxicity. Prescribing remains heterogeneous across population groups, disease states and regimens. This review examines current knowledge of dose-response of oral methotrexate in the setting of rheumatoid arthritis, and how this ...

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial.

Anti-drug antibodies (ADA) are responsible for decreased adalimumab efficacy in axial spondyloarthritis (SpA). We aimed to evaluate the ability of methotrexate (MTX) to decrease adalimumab immunisation.

The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review.

This study aimed to determine the efficacy of different Leucovorin regimens to reduce oral mucositis in children with acute lymphoblastic leukemia after high-dose Methotrexate (HD-MTX).

Subcutaneous Methotrexate versus oral form for treatment and prophylaxis of chronic plaque Psoriasis.

Crocin ameliorates methotrexate-induced liver injury via inhibition of oxidative stress and inflammation in rats.

Methotrexate (MTX) is used commonly in the treatment of various cancers and inflammatory diseases; nevertheless, the associated hepatotoxicity has limited its clinical application. Crocin (CRO) is described as a natural carotenoid with analgesic, antioxidant, and antiinflammatory properties. This study aimed to determine the effects of CRO on MTX-induced hepatotoxicity.

Comparison between Methotrexate and Mycophenolate Mofetil monotherapy for the control of Non- Infectious Ocular Inflammatory Diseases.

To compare mycophenolate mofetil (MMF) to methotrexate (MTX) as corticosteroid-sparing therapy for ocular inflammatory diseases.

Severe, Fatal Methotrexate-related Neurotoxicity in 2 Adolescent Patients With ALL.

Neurotoxicity is a well-documented adverse effect of methotrexate in the treatment of pediatric cancers. The spectrum of symptoms is broad, can include stroke-like episodes and seizures, and classically resolves within days. The majority of patients tolerate subsequent doses without recurrence of symptoms. The population of patients who experience persistent and irreversible neurological symptoms is poorly described, with the existing literature suggestive of a relationship with radiation therapy. The autho...

Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia.

To develop and validate a population pharmacokinetic model of Methotrexate (MTX) in Mexican children with acute lymphoblastic leukemia (ALL) for the design of personalized dosage regimens based on the anthropometric and physiological characteristics of each patient.

Real-World Comparative Effectiveness of Adalimumab, Etanercept, and Methotrexate: A Swedish Register Analysis.

The advent of biosimilars may render Etanercept (ETN) and Adalimumab (ADA) viable alternatives to methotrexate (MTX) as first line systemics in psoriasis. However, real-world relative effectiveness data comparing ADA and ETN to MTX are limited.

Intracranial methotrexate-associated lymphoproliferative disorder in rheumatoid arthritis: A case report.

Methotrexate (MTX) is widely used as an anchor drug for the treatment of rheumatoid arthritis (RA) because of its ability to control pain and inflammation. However, few studies have shown that long-term MTX use can lead to lymphoproliferative disorders (LPDs) in these patients. Here we describe a rare case of intracranial MTX-associated LPD in a patient with RA.

Early predictive factors of single dose methotrexate outcome in patients with ectopic pregnancy.

Two-dose versus single-dose methotrexate for treatment of ectopic pregnancy.

Clinico-genetic model to predict methotrexate intolerance in rheumatoid arthritis.

Methotrexate is the gold-standard DMARD in rheumatoid arthritis but is often associated with "mild" adverse effects like intolerance or laboratory abnormalities. Although non-life threatening, they are responsible for drug discontinuation in 17-50%. There is limited data on clinical and genetic markers that predict their occurrence.


Quick Search